GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » PB Ratio

CervoMed (CervoMed) PB Ratio : 18.92 (As of May. 13, 2024)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-13), CervoMed's share price is $24.5966. CervoMed's Book Value per Share for the quarter that ended in Dec. 2023 was $1.30. Hence, CervoMed's PB Ratio of today is 18.92.

The historical rank and industry rank for CervoMed's PB Ratio or its related term are showing as below:

CRVO' s PB Ratio Range Over the Past 10 Years
Min: 0.35   Med: 10.1   Max: 19.86
Current: 18.92

During the past 13 years, CervoMed's highest PB Ratio was 19.86. The lowest was 0.35. And the median was 10.10.

CRVO's PB Ratio is ranked worse than
94.97% of 1313 companies
in the Biotechnology industry
Industry Median: 2.48 vs CRVO: 18.92

During the past 3 years, the average Book Value Per Share Growth Rate was -64.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CervoMed was -56.80% per year. The lowest was -73.90% per year. And the median was -61.50% per year.

Back to Basics: PB Ratio


CervoMed PB Ratio Historical Data

The historical data trend for CervoMed's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed PB Ratio Chart

CervoMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 2.05 0.89 - 5.87

CervoMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.52 0.48 2.74 5.87

Competitive Comparison of CervoMed's PB Ratio

For the Biotechnology subindustry, CervoMed's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CervoMed's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's PB Ratio distribution charts can be found below:

* The bar in red indicates where CervoMed's PB Ratio falls into.



CervoMed PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

CervoMed's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=24.5966/1.3
=18.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


CervoMed  (NAS:CRVO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


CervoMed PB Ratio Related Terms

Thank you for viewing the detailed overview of CervoMed's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed (CervoMed) Business Description

Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

CervoMed (CervoMed) Headlines

From GuruFocus